spliceosome

Thailanstatin A is an ultra-potent inhibitor of eukaryotic RNA splicing (IC50 = 650 nM). It inhibits multiple cancer cell lines via non-covalent binding to the SF3b subunit of the U2 snRNA subcomplex of the spliceosome, displaying low-nM to sub-nM IC50s. Thailanstatin A, as a payload for ADCs, is conjugated to the lysines on trastuzumab, yielding linker-less ADC.

Pladienolide B is a potent spliceosome inhibitor, a macrolide isolated from Streptomyces obtusususus Mer-12, which targets the SF3B1 subunit of the spliceosome.Pladienolide B exerts its antitumor effects by inhibiting pre-mRNA splicing and inducing necrosis.Pladienolide B possesses antitumor activity and can be used to study leukemia and lymphoid tumors. Pladienolide B has antitumor activity and can be used to study leukemia and lymphoid tumors.

GPS167 is a specific small-molecule splicing regulator and SRSF10 inhibitor that modulates BCLAF1 alternative splicing with an IC50 of 2 μM in human colorectal HCT116 cells, while also directly inhibiting CLK1, CLK2, and CLK4 but not SRPK1 or DYRK1A, positioning it as a mechanistically well-defined probe for studying spliceosome regulation and kinase-dependent RNA processing.

(16R,17S)-FD-895, an analogue of FD-895, is a potent in vivo spliceosome modulator. It retains similar antiproliferative activity to FD-895. (16R,17S)-FD-895 can be used for colon cancer research.

Z6466608628 is a selective molecular glue (molecule glue) degrader for PPIL4, with an EC50 value of 0.34 μM. PPIL4 acts as a modulator of the BACR spliceosome and is crucial for cerebrovascular development. Z6466608628 is applicable in intracranial aneurysm (IA) research.

E7107 is a first-in-class inhibitor of precursor messenger ribonucleic acid spliceosome.

Madrasin (DDD00107587) is a potent and cell penetrant splicing inhibitor that interferes with the early stages of spliceosome assembly.

Ipivivint, a first-in-class, orally active and potent CDC-like kinase (CLK) inhibitor, inhibits CLK1 (IC50=1.4 μM), CLK2 (IC50=0.002 μM) and CLK3 (IC50=0.022 μM). Ipivivint reduces Wnt pathway signaling gene expression through inhibiting CLK activity and serine and arginine rich splicing factor (SRSF) phosphorylation and disrupting spliceosome activity. Ipivivint can be used for the research of cancer[1]. Ipivivint (SW480 cells; 0.01~10 μM; 1 hour) potently inhibits SRSF5/6 phosphorylation[1].Ipivivint (SW480 cells; 0.03 μM~3 μM; 48 hour) induced apoptosis[1]..Ipivivint (HEK-293T cells; 0.03 μM~3 μM; 1 hour) inhibits Wnt/β-catenin signaling induced by Wnt3a[1].Ipivivint (SW480 cells; 0.3~10 μM; 6 hour) increases nuclear speckle enlargement[1].Ipivivint (SW480 cells; 0.3~3μM; 24hours) significantly decreases expression of Wnt target genes (AXIN2, LEF1, MYC, and TCF7) and TCF7L2. SM08502 (SW480 cells; 0.03~3μM; 24hours) inhibits cytoplasmic or nuclear fractions protein expression. Ipivivint (NCI-N87 cells) inhibits proliferation[1].Ipivivint strongly inhibits Wnt pathway signaling activity (EC50 = 0.046 μM) in SW480 colon cancer cells[1]. Ipivivint (25 mg/kg; p.o.) potently inhibits tumor SRSF6 phosphorylation[1]. [1]. Tam BY, et al. The CLK inhibitor SM08502 induces anti-tumor activity and reduces Wnt pathway gene expression in gastrointestinal cancer models. Cancer Lett. 2020;473:186-197.

Hinokiflavone, a novel modulator of pre-mRNA splicing activity both in vitro and in cellulo, inhibits the assembly of the spliceosome, particularly blocking the formation of the B complex. Additionally, it acts as a SUMO protease inhibitor by impeding the activity of sentrin-specific protease 1 (SENP1). Hinokiflavone also demonstrates significant cytotoxicity, including the inhibition of MMP-9.

18-Deoxyherboxidiene (RQN-18690A) is a potent inhibitor of angiogenesis that selectively acts on SF3b, a subcomplex of the U2 small nuclear ribonucleoprotein (snRNP) in the spliceosome. It inhibits migration and tube formation in human umbilical vein endothelial cells (HUVEC) without significant cytotoxicity and has potential for cancer research.

Spliceostatin A is an anticancer agent and splicing inhibitor that inhibits the splicing mechanism of the spliceosome and inhibits mitotic clonal expansion and adipogenesis.Spliceostatin A induces cell cycle arrest in the G1 and G2/M phases, and induces apoptosis.

PTBP1 α3-helix derived peptide P1 TFA is a cell-permeable, rationally designed stapled peptide that inhibits RNA binding by the Polypyrimidine Tract-Binding Protein 1 (PTBP1). PTBP1 α3-helix derived peptide P1 TFA is used in RNA-binding protein interaction research systems to study inhibition of PTBP1–RNA complex formation and modulation of post-transcriptional gene regulation. PTBP1 α3-helix derived peptide P1 TFA is further applied in mechanistic molecular biology studies investigating spliceosome-associated regulatory pathways and RNA processing dynamics in cellular models.

NSC 194308 specifically enhances binding of the U2AF2 subunit to pre-mRNA, capturing early spliceosome assembly and killing leukaemia cell lines harbouring spliceosome mutations. It is applicable for studying pre-mRNA splicing dysregulation.